Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2020 Earnings Conference Call - Final Transcript

Aug 10, 2020 • 04:30 pm ET


Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by, and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference call may be recorded.

I would now like to hand the conference call over to Ben Church, Corporate Communications at Esperion. Please go ahead, sir.

Ben Church

[Technical Issues] I am on the Corporate Communications team here at Esperion. With me on today's call are Tim Mayleben, President and Chief Executive Officer; Mark Glickman, Chief Commercial Officer; and Rick Bartram, Chief Financial Officer.

I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to the risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 10, 2020. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast.

As a reminder, this conference call and webcast are being recorded and archived. We issued a press release this afternoon detailing the content of today's call. A copy can be found at within Investors and Media section. We will begin with prepared comments and then open the call for your questions. Following today's call, the team will be available for follow-up questions. Please e-mail to schedule 15 minutes to speak with the team.

I'd now like to turn the call over to our President and CEO, Tim Mayleben. Tim?

Tim Mayleben

Thank you, Ben. Good afternoon and thank you to everyone joining us on today's conference call. As we all know, the last several months of 2020 have been unlike any other time in history. We are living in unprecedented times, where we see life shifting almost daily as communities, states, countries and the world attempt to reduce the spread of COVID-19, while also minimizing the impact to everyday life. Our hearts go out to those who have experienced losses and we thank the health care workers, researchers and others serving on the front lines of this pandemic.

During this time, we've also been reminded of the importance of managing chronic cardiovascular health conditions, given the recognition that cardiovascular disease is a co-morbidity for COVID-19 and that many people are less active due to stay-at-home orders and are reluctant to see or unable to see their health care providers. So more than ever, we view our singular focus on lipid management as a strength that will help us deliver on our commitment to bringing affordable and convenient oral once-daily non-statin LDL-cholesterol lowering medicines to the